Skip to content

Tolerance and Acceptability Evaluation AYMES Cardiff

Tolerance and Acceptability Evaluation AYMES Cardiff

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04703894
Enrollment
17
Registered
2021-01-11
Start date
2019-11-06
Completion date
2020-01-13
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Brief summary

To evaluate tolerance and acceptability of 'CARDIFF' in patients requiring supplementary oral nutritional support compared with currently available alternatives.

Detailed description

To evaluate tolerance and acceptability of 'CARDIFF' in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference, convenience etc. To obtain data to support an ACBS submissions for 'CARDIFF' (to allow for prescription in the community at NHS expense).

Interventions

DIETARY_SUPPLEMENTAYMES 'CARDIFF'

AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.

Sponsors

Aymes International Limited
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and female patients. * ≥ 18 years of age. * Patients of the intended target group (e.g. MUST score ≥ 1) with an anticipated period of nutritional support ≥ 30 days. * Patient is able and willing to provide written informed consent.

Exclusion criteria

* Patients with medical or dietary contraindication to any feed ingredients. * Patients requiring sole enteral tube feeding or parenteral nutrition. * Patients with significant renal (requiring dialysis) or hepatic impairment (e.g. hepatitis.) * Patients with dysphagia requiring levels 1, 2, 3 or 4 thickened fluids. * Patients with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms. * Patients for whom the investigator has concerns regarding the ability or willingness of the patient and or carer to comply with protocol requirements. * Participation in any other studies involving investigational or marketed products concomitantly or within 2 weeks prior to entry into the study.

Design outcomes

Primary

MeasureTime frameDescription
Gastro-Intestinal Tolerance when consuming AYMES CARDIFF30 daysTo assess gastro-intestinal tolerance of 'CARDIFF' in patients in the community requiring oral nutritional supplementation. Monitoring includes recording the number of any GI complaints via a daily diary.

Secondary

MeasureTime frameDescription
Acceptability and Palatability of Consuming the Nutritional Supplement: questionnaire30 daysTo assess the acceptability of 'CARDIFF' in patients in the community requiring oral nutritional supplementation. At the end of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new supplement drink. A 5 point hedonic scale will be used.
Compliance30 daysTo assess the compliance of patients to 'CARDIFF' by daily completion of a compliance diary, comparing consumed versus prescribed amount.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026